EGFR and colorectal cancer: For example, colorectal cancer patients with wild type proto-oncogene KRAS or BRAF benefit often from treatment with monoclonal antibodies targeting the epidermal growth factor receptor (EGFR) (Amado et al., 2008; Karapetis et al., 2008; Di Nicolantonio et al., 2008).